- Treatment with ADO09, a formulation comprising pramlintide and the A21G human insulin analog, was associated with a greater reduction in postprandial blood glucose (ppBG) than insulin lispro in patients with type 1 diabetes (T1D).
Why this matters
- Some individuals with T1D have difficulties achieving glycemic control using insulin lispro alone.
- A total of 24 patients with T1D received either ADO09, 7.5 U human insulin and 45 µg pramlintide (Ins&Pram), or insulin lispro immediately prior to consuming a mixed meal containing 53% carbohydrate.
- Treatment was combined with 1 g paracetamol to assess gastric emptying.
- Funding: None reported.
- Treatment with ADO09 was associated with >95% reduction in ppBG excursions in the first hour following the meal (mean ± standard deviation ∆AUC blood glucose [BG] 0-1 hour: 1.4±9.9 vs 43.5±15.3 mg*hour/dL; P<.0001>
- ADO09 was also associated with significant improvement in maximum ppBG (∆BGmax, 87.0±35.5 mg/dL) vs insulin lispro (109.2±31.1 mg/dL; P=.0133) and Ins&Pram (109.4±44.3 mg/dL; P=.0357).
- ADO09 was similar to Ins&Pram with regard to gastric emptying time (Tmax_paracetamol: 2.30±1.49 vs 2.38±1.36 hours, P=NS) but was significantly slower than insulin lispro (0.76±0.73 hours; P<.0001>
- Treatments in the study were well tolerated, and adverse events were rare.
- Small sample size.